featured
Immunogenicity and Reactogenicity of BNT162b2 Booster in ChAdOx1-S–Primed Participants
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Immunogenicity and Reactogenicity of BNT162b2 Booster in ChAdOx1-S-Primed Participants (CombiVacS): A Multicentre, Open-Label, Randomised, Controlled, Phase 2 Trial
Lancet 2021 Jun 25;[EPub Ahead of Print], AM Borobia, AJ Carcas, M Pérez-Olmeda, L Castaño, MJ Bertran, J García-Pérez, M Campins, A Portolés, M González-Pérez, MT García Morales, E Arana-Arri, M Aldea, F Díez-Fuertes, I Fuentes, A Ascaso, D Lora, N Imaz-Ayo, LE Barón-Mira, A Agustí, C Pérez-Ingidua, A Gómez de la Cámara, JR Arribas, J Ochando, J Alcamí, C Belda-Iniesta, J FríasFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.